Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The North America Gummy Market is expected to witness market growth of 11.7% CAGR during the forecast period (2021-2027).
read more
The Insight Partners published latest research study on "Diet Pills Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product Type (Prescription, Over the Counter Drugs and Herbal Supplements), Application (Appetite Suppression, Fat Blocking, Metabolism Raising Pills, and Others), Age Group (Teenagers and Adults), and Distribution ...
read more
The global blister packaging market size is expected to reach $46.74B in 2030 and register a revenue CAGR of 6.8% over the forecast period, according to a report by Reports and Data. Cost-effectiveness of blister packaging and tamper-evident design for product protection are the key factors expected to drive market revenue growth over the forecast ...
read more
Active pharmaceutical ingredient (API) supplier PharmaZell, and Novasep, a contract development and manufacturing organization (CDMO) focused on complex small molecules and ADCs, are merging following negotiations begun in September 2021.
read more
Novartis announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.
read more
Ardelyx, Inc. announced multiple presentations covering additional positive clinical observations of XPHOZAH at the National Kidney Foundation 2022 Spring Clinical Meetings (NKF SCM2022).
read more
NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases,announced that it has enrolled and dosed the first healthy volunteer in its pharmacokinetic (PK) study of its lead combination drug candidate PrimeC developed for the treatment of amyotrophic lateral sclerosis (ALS).
read more
ANI Pharmaceuticals, Inc. announced the launch of Misoprostol Tablets, 100 mcg and 200 mcg.
ANI’s Misoprostol Tablets are the generic version of the Reference Listed Drug (RLD) Cytotec®.
read more
Cambrex announced the completion of a $50 million expansion of its large-scale active pharmaceutical ingredient (API) manufacturing capabilities at its Charles City, Iowa facility. The startup of the new manufacturing space is the culmination of a two-year project, originally announced in 2020, to increase the capacity of Cambrex's flagship API ...
read more
The grapeseed extract market estimates a market value of USD 60.78 million from 2021 to 2026 as per the latest market report by Technavio.
read more
Alzamend, an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, announced that it contracted with Altasciences Clinical Kansas and iResearch Atlanta, LLC to manage and conduct, respectively, its Phase IIA multiple ascending dose (“MAD”) study...
read more
Yourway, an integrated courier and clinical packager in the clinical trials supply chain market, announced the expansion of its controlled ambient capabilities in Allentown, Pennsylvania.
read more
Biohaven has secured additional commercial insurance coverage for Nurtec ODT starting in April 2022 that expands the total number of commercial lives covered to 96 percent or approximately 255 million people via all channels.
read more
Catalent announced that it has completed the installation and commissioning of four new high throughput ‘high-bay’ CGMP manufacturing suites at its facility in Kansas City, Missouri, to increase its capacity and capabilities for producing oral solid dose forms.
read more
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced clinical development progress for LMN-201, an investigational orally delivered cocktail to treat and prevent C. difficile infection (CDI).
read more